SPINE
CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis
This report has been verified
by one or more authors of the
original publication.
Arthritis Res Ther. 2016 Jan 20;18(1):25
250 ankylosing spondylitis patients were randomized to receive 5mg/kg of either CT-P13 or Infliximab through intravenous infusion for 54 weeks. The purpose of this study was to compare CT-P13, a biosimilar drug, to a known efficacious treatment of this pathology to determine its efficacy, immunogenicity, pharmacokinetics, and safety. The findings displayed similar results between groups for all patient reported efficacy outcomes, adverse events, and pharmacokinetic parameters, as well as in the proportion of patients testing positive for anti-drug antibodies at 54 weeks.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
